IMVT Immunovant Inc

Price (delayed)

$39.02

Market cap

$5.64B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.96

Enterprise value

$5.38B

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous ...

Highlights
Immunovant's debt has shrunk by 66% YoY and by 33% QoQ
IMVT's quick ratio is down by 48% year-on-year but it is up by 4.7% since the previous quarter
IMVT's net income is down by 44% YoY and by 4.4% from the previous quarter
The equity has contracted by 36% YoY and by 16% from the previous quarter

Key stats

What are the main financial stats of IMVT
Market
Shares outstanding
144.66M
Market cap
$5.64B
Enterprise value
$5.38B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
20.25
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$255.42M
EBITDA
-$254.05M
Free cash flow
-$209.82M
Per share
EPS
-$1.96
Free cash flow per share
-$1.6
Book value per share
$1.93
Revenue per share
$0
TBVPS
$2.23
Balance sheet
Total assets
$292.07M
Total liabilities
$40.26M
Debt
$614,000
Equity
$251.81M
Working capital
$250.92M
Liquidity
Debt to equity
0
Current ratio
7.23
Quick ratio
6.74
Net debt/EBITDA
1.06
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-67.8%
Return on equity
-76.8%
Return on invested capital
N/A
Return on capital employed
-101.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMVT stock price

How has the Immunovant stock price performed over time
Intraday
-2.28%
1 week
2.04%
1 month
15.65%
1 year
171.73%
YTD
119.83%
QTD
1.64%

Financial performance

How have Immunovant's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$269.96M
Net income
-$255.26M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 51% year-on-year and by 4.7% since the previous quarter
IMVT's net income is down by 44% YoY and by 4.4% from the previous quarter

Growth

What is Immunovant's growth rate over time

Valuation

What is Immunovant stock price valuation
P/E
N/A
P/B
20.25
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Immunovant's EPS has decreased by 28% YoY and by 2.1% QoQ
The stock's price to book (P/B) is 144% more than its 5-year quarterly average of 8.3 and 107% more than its last 4 quarters average of 9.8
The equity has contracted by 36% YoY and by 16% from the previous quarter

Efficiency

How efficient is Immunovant business performance
IMVT's return on equity has dropped by 96% year-on-year and by 16% since the previous quarter
IMVT's return on assets has dropped by 86% year-on-year and by 14% since the previous quarter

Dividends

What is IMVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMVT.

Financial health

How did Immunovant financials performed over time
IMVT's quick ratio is down by 48% year-on-year but it is up by 4.7% since the previous quarter
Immunovant's current ratio has decreased by 46% YoY but it has increased by 6% QoQ
Immunovant's debt is 100% lower than its equity
Immunovant's debt has shrunk by 66% YoY and by 33% QoQ
The equity has contracted by 36% YoY and by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.